AliveCor has received approval from the US Food and Drug Administration (FDA) for its two new algorithms, which provide users with instant feedback on their electrocardiogram (ECG) recordings.
The new analysis processes comprise Normal Detector, which identifies when no abnormalities are detected in an ECG recording and an Interference Detector that identifies if factors have affected the recording making the ECG unreadable.
AliveCor president and CEO Euan Thomson said: "Our goal for creating these two new detectors was to expand our automated services based on the millions of ECGs now in our database and provide patients with the information they have told us they want at their fingertips.
"With these new detection capabilities, patients, along with their healthcare providers can focus on reviewing those ECGs that are most concerning while also working to understand what lifestyle factors may be contributing to both their normal or abnormal recordings."
The new detectors, along with the previously cleared atrial fibrillation (AF) detection algorithm, (AF Detector), provide accurate and relevant real-time interpretations of mobile ECG recordings, noted AliveCor.
The AliveCor Heart Monitor has been developed to record, store and transfer single-channel ECG rhythms. It will also display ECG rhythms and detects the presence of atrial fibrillation and normal sinus rhythm.